6 results
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - ... cells, triggering insulin ... contraindicated in CKD ... Summary #DM2 #diabetes ... #endocrinology
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table Insulin ... modifications Metformin Sulfonylureas ... Improved outcomes in CKD ... comparison #management #endocrinology
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
: Weight-Based Dosing ... (stage IV or V CKD ... #dosing #estimation ... #Weight #Based ... #pharmacology #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Classes: Biguanide, Sulfonylurea ... appropriately • Weight-based ... #Medications #pharmacology ... comparison #table #endocrinology
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Patients With CKD ... patients with T2D, CKD ... and CKD should ... layered evidence-based ... #Diabetes #CKD #
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
oral suspension DOSING ... 25.2 g if needed, based ... patients with CKD ... , HF, or diabetes ... #Hyperkalemia #Pharmacology